München
21.07.25 | 08:04
2,780 Euro
0,00 % 0,000
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 09.07. | Inventiva beruft neue Führungskräfte für Forschung & Entwicklung und regulatorische Angelegenheiten | 4 | Investing.com Deutsch | ||
| 09.07. | Inventiva appoints new R&D president and regulatory affairs executive | 2 | Investing.com | ||
| 09.07. | INVENTIVA: Inventiva names Jason Campagna as President of R&D and Chief Medical Officer and Martine Zimmermann as Executive Vice President of Regulatory Affairs and Quality Assurance | 321 | GlobeNewswire (Europe) | Jason Campagna, MD, PhD, joins Inventiva as President of R&D and Chief Medical Officer, succeeding Pierre Broqua, PhD, and Michael Cooreman, MDMartine Zimmermann, PharmD, joins as Executive Vice President... ► Artikel lesen | |
| 09.07. | Inventiva Receives $10 Mln Milestone Payment From CTTQ For MASH Drug Development | 2 | RTTNews | ||
| 07.07. | Inventiva S.A. - 6-K, Report of foreign issuer | - | SEC Filings | ||
| INVENTIVA SA ADR Aktie jetzt für 0€ handeln | |||||
| 07.07. | INVENTIVA: Inventiva receives $10 million milestone payment from CTTQ | 711 | GlobeNewswire (Europe) | Daix (France), New York City (New York, United States), July 7, 2025 - Inventiva (Euronext Paris and Nasdaq: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on... ► Artikel lesen | |
| 02.07. | INVENTIVA: Inventiva announces the publication in Journal of Hepatology Reports on results of lanifibranor treatment on liver sinusoidal endothelial cells in patients with MASLD/MASH and in preclinical models of the disease | 340 | GlobeNewswire (Europe) | Analysis of liver sinusoidal endothelial cells ("LSEC") from screening and end of treatment biopsies in the Phase 2b NATIVE study showed evidence of LSEC capillarization in patients without MASH, and... ► Artikel lesen | |
| 10.06. | INVENTIVA: Inventiva Announces the Appointment of Renée Aguiar-Lucander to its Board of Directors | 512 | GlobeNewswire (Europe) | Daix (France), New York City (New York, United States), June 10, 2025 - Inventiva (Euronext Paris and Nasdaq: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused... ► Artikel lesen | |
| 27.05. | INVENTIVA: Inventiva to Participate in the Upcoming Jefferies Global Healthcare Conference and UBS Spring Biotech Conference | 334 | GlobeNewswire (Europe) | Daix (France), New York City (New York, United States), May 27, 2025 - Inventiva (Euronext Paris and NASDAQ: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on... ► Artikel lesen | |
| 23.05. | Inventiva S.A. reports Q1 results | 1 | Seeking Alpha | ||
| 23.05. | INVENTIVA: Inventiva reports 2025 First Quarter Financial Information | 370 | GlobeNewswire (Europe) | Cash and cash equivalents at €67.9 million
Daix (France), New York City (New York, United States), May 23, 2025 - Inventiva (Euronext Paris and Nasdaq: IVA) (the "Company"), a clinical-stage biopharmaceutical... ► Artikel lesen | |
| 23.05. | INVENTIVA: Results of the Votes of the Combined Shareholders' General Meeting of May 22, 2025 | 187 | GlobeNewswire (Europe) | Daix (France), New York City (New York, United States), May 23, 2025 - Inventiva (Euronext Paris and Nasdaq: IVA) (the "Company"), a clinical-stage biopharmaceutical company focused on the development... ► Artikel lesen | |
| 22.05. | Inventiva S.A. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 22.05. | Inventiva sets share repurchase program terms post-meeting | 5 | Investing.com | ||
| 22.05. | INVENTIVA: Description of the Share Repurchase Program Covered by the Liquidity Agreement with Kepler Chevreux | 262 | GlobeNewswire (Europe) | Daix, May 22, 2025
Pursuant to Article 241-2 of the AMF General Regulations (Règlement Général de l'Autorité des marchés financiers), the purpose of this description is to present the objectives... ► Artikel lesen | |
| 05.05. | Inventiva secures €116 million second tranche of structured financing of up to €348 million | 2 | Seeking Alpha | ||
| 05.05. | INVENTIVA: Inventiva secures the €116 million second tranche of its structured financing of up to €348 million | 374 | GlobeNewswire (Europe) | Financing follows completion of enrollment of Phase 3 NATiV3 study evaluating lanifibranor in MASH and satisfaction of other specified conditions.
Daix (France), New York City (New York, United... ► Artikel lesen | |
| 02.05. | Inventiva S.A. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 30.04. | INVENTIVA: Combined General Meeting of May 22, 2025 - Availability of the preparatory documents | 282 | GlobeNewswire (Europe) | Daix (France), New York City (New York, United States), April 30, 2025 - Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small... ► Artikel lesen | |
| 30.04. | INVENTIVA: Statement of total voting rights and shares forming the company's share capital as of April 11, 2025 | 260 | GlobeNewswire (Europe) | Article R. 22-10-23 of the French Commercial Code
Market: Euronext ParisISIN code / Mnemo: FR0013233012 / IVAWeb site: www.inventivapharma.com
DateNumber of shares outstandingTotal voting rights... ► Artikel lesen |
1 2 3 Weiter >>
58 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| AURORA CANNABIS | 4,000 | +2,43 % | Stocks in Play: Aurora Cannabis Inc. | ||
| CANOPY GROWTH | 0,974 | +2,20 % | Canopy Growth: Buy, Sell, or Hold in July 2025? | ||
| TILRAY BRANDS | 0,565 | +5,80 % | UNGLAUBLICHE Sondermeldung bei Tilray Aktie: DAS erwischt Anleger heute eiskalt. Dringend lesen und reagieren! | ||
| TEVA | 13,950 | +0,72 % | Teva Pharma stock rating reiterated at Buy by BofA on Austedo growth | ||
| VERTEX PHARMACEUTICALS | 393,65 | -0,48 % | Vertex Pharmaceuticals Incorporated: Vertex Announces Broad Reimbursement Agreement With NHS England for ALYFTREK (Deutivacaftor/Tezacaftor/Vanzacaftor) an Innovative Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis | All eligible people with CF in England can now benefit from this medicine - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that it has reached a broad reimbursement agreement... ► Artikel lesen | |
| ARZNEIWERK AG VIDA | 0,300 | -36,97 % | XETR DELETION OF INSTRUMENTS FROM XETRA - 30.06.2025 | The following instruments on XETRA do have their last trading day on 30.06.2025Die folgenden Instrumente auf XETRA haben ihren letzten Handelstag am 30.06.2025ISIN NameDE000A3EX3G0 GORE German Office... ► Artikel lesen | |
| CRONOS GROUP | 1,753 | +1,62 % | High Tide schließt mit Cronos Group Inc. eine Vereinbarung über Wandelschuldverschreibungen im Wert von 30 Millionen $ ab | CALGARY, AB, und TORONTO, ON, 16. Juli 2025 / IRW-Press / High Tide Inc. ("High Tide" oder das "Unternehmen") (Nasdaq: HITI) (TSXV: HITI) (FWB: 2LYA), das
erfolgreiche, auf den Einzelhandel fokussierte... ► Artikel lesen | |
| VIATRIS | 7,644 | -0,03 % | Why Is Viatris Stock Falling In Pre-market? | WASHINGTON (dpa-AFX) - Viatris Inc. (VTRS) announced that a randomized, double-masked, vehicle-controlled, Phase 3 study to evaluate the efficacy and safety of pimecrolimus 0.3% ophthalmic ointment... ► Artikel lesen | |
| EYEPOINT PHARMACEUTICALS | 9,100 | +1,59 % | EyePoint Pharmaceuticals, Inc.: EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | WATERTOWN, Mass., July 16, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients... ► Artikel lesen | |
| INCYTE | 57,90 | -0,82 % | Incyte: UBS erhöht Kursziel auf 62 US-Dollar aufgrund von Verkaufsaussichten | ||
| BAUSCH HEALTH | 5,378 | -1,01 % | Best Stock to Buy Right Now: Bausch Health vs Canopy Growth? | ||
| EDWARDS LIFESCIENCES | 65,79 | 0,00 % | Should You Add Edwards Lifesciences Stock to Your Portfolio Now? | ||
| IONIS PHARMACEUTICALS | 35,690 | -0,67 % | Ionis: HAE-Medikament Donidalorsen reduziert Anfallsraten in Studie signifikant | ||
| CRESCO LABS | 0,500 | +5,62 % | Cresco Labs Inc. Announces Strategic Restructuring and Plans to Divest California Operations | ||
| ROCKET LAB | 40,400 | -9,01 % | Neu: SpaceX bei Robinhood - Rocket Lab im Depot 2030 | Raumfahrt-Boom an der Börse. Visionen von Robotern auf dem Mars und neue Defense-Anwendungen sorgen für enormen Aufwind. SpaceX-Rivale Rocket Lab ist seit Kauf im Juni 2025 nun 55 Prozent im Depot 2030... ► Artikel lesen |
INVENTIVA SA ADR gehört der Branche Pharma an. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 2,780 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu INVENTIVA SA ADR finden Sie auf Wallstreet Online.